Mission & Strategy

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness.

Our business is built upon biosynthetic technologies – using yeast to create products via fermentation.

Innovative products can stem from novel compounds (novel chemical entities) or from novel production methods (biosynthesis or fermentation) but have as a common theme that they provide patients or consumers with health or wellness benefits that existing products do not provide.

Our key competitive advantages are in creative concept development, cutting edge research and early stage product development and clinical studies. For late stage development and marketing of products, Evolva chooses to work with strategic partners. This business-to-business approach allows us to focus on what we do best while at the same time reducing risk.

We seek to build Evolva as high-growth and sustainably profitable vehicle for achieving our goals and providing our shareholders with good returns.

We believe considering health and wellness in a broad manner – from pharmaceuticals through consumer health to nutrition - has three main benefits for Evolva and our shareholders:

• Market wise, it fits current macro-trends. Global economic and demographic changes mean there is huge growth in the number of “medium-affluent” consumers around the world who desire better health at an affordable price. At the same time, western governments are under increasing pressure to reduce budgets. This creates demand for health and wellness products that are on the one hand appealing, convenient and natural, but on the other hand affordable. This is exactly what Evolva’s technology can provide.

• Technically there are strong synergies for Evolva between the sectors. As one example, whilst our vanillin project is focused on food, compounds related to vanillin have potential utility in analgesia and energy metabolism, creating consumer health and pharmaceutical product opportunities. Similarly our understanding of cardiovascular health, and how to run clinical trials in this sector, can assist us when considering how to develop food ingredients that may have cardiovascular benefits. Such synergies improve the investment returns on our research and development.

• Financially the approach allows us to build a balanced company across a range of products. Products in the consumer health and nutrition sectors have, compared to pharmaceuticals, shorter times to market and a lower spend and risk of technical failure. Whilst margins once on market are ultimately lower, they provide Evolva with a route to sustainable profitability that comes earlier, and at lower risk, than a focus on pharmaceuticals alone. Pharmaceuticals still provide the strongest upside.

Finally, our strategy will itself evolve. We are keenly aware of the need to adapt rapidly in a world that is changing at the speed of thought. And adapting and evolving are fundamental to Evolva’s conception of itself.